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ABSTRACT 
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder (ND) 
defined by the presence of impairing levels of inattentiveness, hyperactivity, and impulsivity. 
These symptoms are often accompanied by impairment in several functional domains, and 
by the presence of symptoms or diagnoses of other disorders, especially other NDs, including 
Autism Spectrum Disorder (ASD). In addition, risky behaviours and health issues are more 
common among individuals with ADHD, as compared to their peers who do not display 
ADHD symptoms. The overall aim of this thesis is to investigate the comorbidity between 
ADHD, ASD and other NDs, in order to clarify shared aetiology, treatment effectiveness and 
adverse health outcomes. 
Study 1 examined the association between clinically diagnosed ASD and ADHD across 
different types of relatives and explored potential differences between low- and high-
functioning ASD (that is, with or without intellectual disability) in the link with ADHD. Data 
for the study came from a linkage of national Swedish registers in order to identify different 
types of relatives, from twins to cousins, and clinical diagnoses of ASD and ADHD. Logistic 
regression was used to estimate the association between ASD and ADHD within the same 
person (within-individual association) and within relative pairs (within-family association). 
Results demonstrated that individuals diagnosed with ASD and their relatives had an increased 
risk of ADHD. The association in twins and siblings was higher than the association in cousins. 
The magnitude of the association was larger in high-functioning ASD. 
Study 2 focused on the phenotypic and aetiological overlap between traits related to ADHD 
and ASD in young adult twins from the general population. Data for the study came from a 
web-based survey within the Swedish Twin Registry. Four different trait dimensions were 
considered: inattention (IA), hyperactivity/impulsivity (HI), repetitive and restricted 
behaviours (RRB), social interaction and communication difficulties (SIC). Structural equation 
modelling was used to decompose the covariance across these trait dimensions into genetic and 
non-genetic influences. Results showed that at the phenotypic level, the correlation between IA 
and RRB was similar to the one between IA and SIC, while the correlation between HI and 
RRB was stronger than the one between HI and SIC. Genetic and non-genetic contributions 
accounted for a similar amount of the covariation across all trait dimensions under study. The 
largest genetic correlation between traits related to ADHD and traits related to ASD was 
between HI and RRB. 
Taken together, results from Study 1 and 2 suggest that comorbidity between ADHD and ASD 
may reflect shared aetiological factors, which are in part of genetic origin and which may be 
specific to certain symptom domains. 
Study 3 tested the association between use of ADHD medication and risk of unintentional 
injuries in children and adolescents with ADHD, including those with co-occurring NDs. Data 
for the study came from a linkage of national Swedish registers. All residents in Sweden with 
at least one diagnosis of ADHD and one diagnosis of unintentional injury were included and 
followed during the study period. Follow-up time was divided into consecutive periods, which 
may be on-treatment or off-treatment, and the rate of injuries during periods on-treatment was 
compared to the rate of injuries during periods off-treatment within the same individual, using 
stratified Cox regression. Results indicated that ADHD medication use was associated with a 
lower rate of all unintentional injuries, among children and adolescents, among males and 
females, and among individuals with NDs, as well as among the subgroup with ASD.  
Study 4 investigated the association between different NDs and the risk of violent victimization 
in adolescents and young adults, considering the role of familial and mediating factors. 
Similarly to Study 1 and 3, a linkage of national Swedish registers was used to identify 
diagnoses of different NDs and inpatient or outpatient visits or deaths due to assault in the study 
population. The association between the NDs and violent victimization was explored using 
Cox regression. Results revealed that being diagnosed with any ND was associated with an 
increased risk of later violent victimization in males and females. After adjustment for familial 
factors and mediators, all the associations were attenuated and only ADHD was associated with 
an increased risk of violent victimization among males and females.  
Taken together, results from Study 3 and 4 suggest that comorbidity between ADHD and other 
NDs does not seem to affect treatment effectiveness with regard to ADHD medication and 
injuries. On the other hand, risk of violent victimization, which seemed to be related to NDs as 
a group, may be specifically linked to ADHD. 
In conclusion, the work presented in this thesis supports the notion that NDs are a group of 
disorders characterised by both general and specific aspects in terms of aetiology, treatment 
effectiveness and negative outcomes.  
 
 
 
  
LIST OF SCIENTIFIC PAPERS 
I. Ghirardi L, Brikell I, Kuja-Halkola R, Freitag CM, Franke B, Asherson P, 
Lichtenstein P, Larsson H.The familial co-aggregation of ASD and ADHD: a 
register-based cohort study. Molecular Psychiatry. 2018 Feb 23(2):257-262. 
II. Ghirardi L, Pettersson E, Taylor MJ, Freitag CM, Franke B, Asherson P, 
Larsson H, Kuja-Halkola R. Genetic and environmental contribution to the 
overlap between ADHD and ASD trait dimensions in young adults: a twin 
study. Psychological Medicine. 2019 Jul;49(10):1713-1721. 
III. Ghirardi L, Chen Q, Chang Z, Kuja-Halkola R, Skoglund C, Quinn PD, 
D’Onofrio BM, Larsson H. Use of medication for attention-
deficit/hyperactivity disorder and risk of unintentional injuries in children and 
adolescents with co-occurring neurodevelopmental disorders. (Accepted for 
publication)  
IV. Ghirardi L, Kuja-Halkola R, Pettersson E, Sariaslan A, Arseneault L, Fazel S,  
D’Onofrio BM, Lichtenstein P, Larsson H. Neurodevelopmental disorders 
and risk of violent victimization: a nation-wide sibling-comparison study in 
Sweden. (Manuscript) 
 
  
CONTENTS 
1 Introduction ..................................................................................................................... 1 
2 Background ...................................................................................................................... 2 
2.1 Attention-deficit/hyperactivity disorder (ADHD) ................................................ 2 
2.1.1 Diagnostic assessment ............................................................................... 2 
2.1.2 Epidemiology ............................................................................................ 3 
2.1.3 Developmental course ............................................................................... 4 
2.2 Comorbidities of ADHD ....................................................................................... 4 
2.2.1 Neurodevelopmental disorders ................................................................. 5 
2.3 Aetiology of ADHD .............................................................................................. 5 
2.3.1 Shared aetiology between ADHD and ASD ............................................ 6 
2.4 Adverse outcomes of ADHD ................................................................................ 7 
2.5 Treatment of ADHD .............................................................................................. 7 
2.5.1 Non-pharmacological treatment of ADHD .............................................. 7 
2.5.2 Pharmacological treatment of ADHD ...................................................... 8 
2.5.3 Pharmacological treatment of ADHD in the context of other NDs ......... 8 
2.6 An epidemiological approach ............................................................................... 9 
2.6.1 Causal inference in epidemiology ............................................................ 9 
2.6.2 Causation in genetically informative studies .......................................... 10 
2.6.3 Quantitative genetic studies .................................................................... 11 
2.6.4 The role of genomics in epidemiology ................................................... 11 
3 Aims ............................................................................................................................... 13 
3.1 Overarching aim .................................................................................................. 13 
3.2 Specific aims ........................................................................................................ 13 
4 Data and measures ......................................................................................................... 14 
4.1 Swedish National registers .................................................................................. 14 
4.1.1 Main measures in the registers ................................................................ 15 
4.2 YATSS ................................................................................................................. 17 
4.2.1 Measures of ADHD and ASD trait dimensions in YATSS ................... 17 
5 Methods ......................................................................................................................... 20 
5.1 Study designs ....................................................................................................... 20 
5.1.1 Familial co-aggregation studies .............................................................. 20 
5.1.2 Twin studies ............................................................................................ 20 
5.1.3 Within-cluster comparison ...................................................................... 21 
5.2 Statistical methods ............................................................................................... 22 
5.2.1 Logistic regression .................................................................................. 22 
5.2.2 Structural equation modelling ................................................................. 22 
5.2.3 Cox regression ......................................................................................... 23 
6 Study summaries and results ......................................................................................... 25 
6.1 Shared aetiology between ADHD and ASD ...................................................... 25 
6.1.1 Familial co-aggregation of ASD and ADHD (Study 1)......................... 25 
6.1.2 ADHD and ASD trait dimensions in adults (Study 2) ........................... 27 
6.2 ADHD and other NDs: outcomes and treatment effectiveness ......................... 29 
6.2.1 ADHD medication and injuries and the role of co-occurring 
neurodevelopmental disorders (Study 3) ................................................ 30 
6.2.2 Neurodevelopmental disorders and victimization (Study 4) ................. 32 
7 Discussion ...................................................................................................................... 36 
7.1 Main findings and implications .......................................................................... 36 
7.1.1 Shared aetiology between ADHD and ASD .......................................... 36 
7.1.2 ADHD and other NDS: outcomes and treatment effectiveness ............ 38 
7.2 Methodological considerations ........................................................................... 39 
7.2.1 Measures .................................................................................................. 39 
7.2.2 Methods ................................................................................................... 40 
7.3 Ethical considerations ......................................................................................... 42 
7.3.1 Data collection and handling .................................................................. 42 
7.3.2 Results communication and interpretation ............................................. 43 
8 Conclusions ................................................................................................................... 44 
9 Acknowledgments ......................................................................................................... 45 
10 References ..................................................................................................................... 48 
 
  
  
LIST OF ABBREVIATIONS 
A  Additive genetic influences 
ADHD Attention-deficit/hyperactivity disorder 
ASD Autism spectrum disorder 
ATC Anatomical therapeutic chemical 
C  Shared environmental influences 
CD Conduct disorder 
CDR Cause of death register 
CI Confidence interval 
D Dominant genetic influences  
DAG Directed acyclic graph  
DZ Dizygotic (twins) 
DSM Diagnostic and Statistical Manual of Mental Disorders 
E  Unique environmental influences 
GWAS Genome-wide association study 
h2 Heritability 
HI Hyperactivity/impulsivity 
HKD Hyperkinetic disorder 
HR Hazard ratio 
IA Inattention 
ICD International Classification of Diseases and Related Health 
Problems 
ID Intellectual disability 
IQ Intelligence quotient 
MBR Medical birth register 
MGR Multi-generation register 
MZ Monozygotic (twins) 
NCR National crime register  
ND Neurodevelopmental disorder 
NPR National patient register 
OR Odds ratio 
PDR Prescribed drug register 
PGC Psychiatric Genomics Consortium 
PIN Personal identification number 
PRS Polygenic risk score  
r Correlation 
rg Genetic correlation 
RRB Repetitive and restricted behaviors 
RCT Randomized controlled trial 
SEM Structural equation modelling 
SIC Social interaction and communication difficulties 
SNP Single nucleotide polymorphism 
STR Swedish twin register 
TBI Traumatic brain injury 
TPR Total population register 
WHO World Health Organization 
YATSS Young Adult Twin Study in Sweden 
 
  1 
1 INTRODUCTION  
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder (ND) 
characterized by age-inappropriate levels of inattentiveness, hyperactivity, and impulsivity.1,2 
Individuals diagnosed with ADHD often present with some features or a diagnosis of other 
NDs, including autism spectrum disorder (ASD),3-6 intellectual disability (ID),7 learning 
disability,3,6 and language problems.3,8 Furthermore, ADHD is associated with several risky 
behaviours and adverse health outcomes.9-12  
The heritability of ADHD is estimated to be one of the highest among psychiatric disorders.13 
However current knowledge about aetiology and pathophysiology of the disorder is limited. 
In addition, it remains unclear the extent to which aetiological factors underlying liability to 
ADHD are shared with other NDs and whether certain symptoms of ADHD may be more 
strongly linked to other NDs.  
Several treatment options are available for the management of ADHD symptoms, including 
pharmacological14,15 and non-pharmacological interventions.15-17 However, little is known 
about whether such treatment options remain equally effective for individuals who present 
with both ADHD and other NDs.  
Furthermore, considering the high rates of co-occurrence with other disorders, especially 
NDs, an important aspect that remains unclear is whether the association between ADHD 
and risky behaviours and adverse health outcomes is specific to ADHD or is present also 
among other NDs.   
This thesis seeks to extend previous knowledge about the comorbidity between ADHD, ASD 
and other NDs, focusing on shared aetiology, treatment effectiveness and adverse health 
outcomes.  
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2 BACKGROUND 
2.1 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) 
The term “Attention Deficit/Hyperactivity Disorder” dates back to 1980, when it was 
introduced in the revised third edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-III-R).18 DSM-III-R listed a number of separate symptoms for for inattention, 
impulsivity, and hyperactivity. With the fourth edition of DSM (DSM-IV), published in 1994, 
ADHD was described as a disorder characterized by two separate dimensions: the deficit in 
attention and the component related to hyperactivity/impulsivity. In addition, DSM-IV 
introduced ADHD subtypes, based on symptoms manifestation: predominantly inattentive, 
predominantly hyperactive-impulsive, and combined.19 The fifth edition of DSM (DSM-5), 
published in 2013 has implemented a change in the terminology used for ADHD subtypes.1 
The term “subtype” has now been replaced by the term “presentation”. This implies that ADHD 
presentation may, for example, change during development.20 The “combined type” 
presentation of ADHD described by DSM-5 is similar to, but does not completely overlap with, 
“hyperkinetic disorder” (HKD), as defined by International Classification of Disorders, Tenth 
Edition (ICD-10).2 Although the descriptions of behavioural symptoms in DSM and ICD are 
essentially the same, a diagnosis of HKD in the ICD-10 requires greater pervasiveness of 
symptoms in different domains (that is, across inattention, hyperactivity and impulsivity) and 
across different settings (for example, both at home and at school or at work). Therefore, HKD 
can be regarded as a more severe subcategory of ADHD (or even of the combined presentation 
of ADHD). In the new revision of ICD (ICD-11), the name of the disorder has changed to 
“Attention deficit hyperactivity disorder”, which is now listed in the “Neurodevelopmental 
disorders” category. The description of ADHD in ICD-11 resembles DSM-5 criteria and 
describes the same presentations as DSM-5.21  
2.1.1 Diagnostic assessment 
According to European guidelines, clinical assessment of ADHD usually includes: an 
evaluation of clinical symptoms and psychosocial functioning in different domains and 
settings; a physical examination; an investigation of medical and of developmental history; 
reports from different informants, such as parents and teachers for children.22-24  
Although ADHD is defined as a single disorder, there is great variability in the symptom profile 
of diagnosed individuals, as well as in the degree of impairment in daily functioning. Further, 
in recent years, evidence has accumulated supporting the view of ADHD as a set of symptoms 
representing the extreme end of normally distributed traits in the population.25 Several rating 
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scales are available for the assessment of ADHD symptoms and they have been used in 
community and in clinical samples.26 These inventories assess possibly problematic 
behaviours, which are usually rated by an informant, such as a parent or a teacher, in the case 
of children. Examples of widely used scales for ADHD evaluation are Conners’ Rating Scales 
(CRS) 27,28 and ADHD Rating Scale-IV (ADHD-IV).29,30 However, for individuals who seek 
help and come in contact with health-care for the first time as adults, self-report is often the 
main source of information. The Adult Self-Report Scale (ASRS) and the ASRS Screener (a 
shorter version of the ASRS including only six items) are official instruments of the World 
Health Organization, which have been developed to evaluate ADHD symptoms in adults.31,32 
Another instrument used to assess symptoms in adults is the Conners’ Adult ADHD Rating 
Scales (CAARS),33 which includes both a version for self-report and a version for observer-
report. These scales are often used in research to collect more detailed information on traits 
related to ADHD in the general population and investigate whether the variability at the 
phenotypic level may reflect heterogeneity in the aetiological architecture of the disorder.  
2.1.2 Epidemiology 
ADHD is among the most common psychiatric disorders in childhood. According to the most 
recent meta-analysis on the prevalence of mental disorders in childhood and adolescence, the 
estimated worldwide prevalence of ADHD is 3.4% (95% CI 2.6–4.5).34 However, pooled 
prevalence estimates indicate great heterogeneity, due to differences in study methods. The 
factors that seem to influence prevalence estimates are diagnostic criteria (that is, DSM vs 
ICD), requirement of functional impairment, and source of information (that is, one vs multiple 
informants).35 The prevalence of ADHD is higher in males than in females, with a male-to-
female ratio of 4:1 in studies based on clinical samples and 2.4:1 in studies based on population-
derived samples.36  
Increasing attention has been given to how ADHD manifests in adults in the last decade. A 
meta-analysis of six published studies based on adult samples found a pooled estimate of 
ADHD prevalence equal to 2.5% (95% CI 2.1–3.1),37 with a lower estimate in the European 
sample.38 In addition, a recent study has shown that, although there may be differences in 
clinical presentation of ADHD between women and men, rates of persistent ADHD seem to be 
comparable across sexes.39 Despite the increased interest in ADHD in adults, the disorder is 
still under-diagnosed and more research is needed to understand better its manifestations and 
associated impairment.40,41 
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2.1.3 Developmental course 
Symptoms of ADHD usually have their onset during childhood and most individuals are 
diagnosed after starting school.42 Among those children who are diagnosed with ADHD during 
pre-school years, the majority seem to continue to meet criteria for ADHD later in childhood,42-
46 while some of them may remit partially or completely.42,47 The available longitudinal 
research indicates that both some level of stability and some level of change characterize the 
trajectory of ADHD throughout development. In general, symptoms of inattentiveness seem to 
be more persistent than symptoms of hyperactivity and impulsivity.48,49 
Although historically conceived as a childhood condition, in the last decade there has been 
increased recognition that ADHD is a life-long condition that can be reliably diagnosed in 
adults.37,38,50-52 A substantial proportion of individuals diagnosed in childhood continue to 
suffer from impairing levels of symptoms in adulthood and a minority of them meet criteria for 
a diagnosis.53-55 More recently, a number of studies have reported that individuals manifesting 
ADHD symptoms as adults may not have presented these symptoms as children.54,56 This line 
of evidence is in contrast with the current conceptualization of ADHD as a childhood-onset 
disorder, as described by current diagnostic criteria. Whether these findings may be explained 
by the action of protective factors during childhood that would mitigate the impact of the 
symptoms or by the existence of an “adult-onset” form of ADHD is still debated.    
2.2 COMORBIDITIES OF ADHD  
In children and adolescents, ADHD is often associated with other neuropsychiatric 
disorders.3,22,57 In addition, there is some evidence indicating that the presence of co-occurring 
disorders may lead to poorer functioning in several domains.3,10 Nevertheless,  individuals who 
meet diagnostic criteria for ADHD and other conditions, or even just display some symptoms 
of other disorders, are often excluded from studies in order to compare groups that are more 
homogenous. For example, randomized controlled trials (RCTs) aimed at testing efficacy of 
interventions for ADHD symptoms and large genetic studies aimed at identifying genetic 
variants associated with the disorder, such as the Psychiatric Genomics Consortium (PGC), 
have typically excluded individuals with other neuropsychiatric disorders or low intelligent 
quotient (IQ). Therefore, it is not clear whether findings based on samples defined by such 
strict exclusion criteria may generalize to the larger group of ADHD patients, who often present 
with symptoms or a diagnosis of another disorder. 
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2.2.1 Neurodevelopmental disorders 
ADHD often co-occurs with other neurodevelopmental disorders (NDs). According to DSM-
5, NDs are a group of disorders that typically have their onset early during development and 
are characterized by developmental deficits that cause impairment in one or more areas of 
funtioning.1 In addition to ADHD, NDs include: ASD, intellectual disability (ID), 
communication disorders, learning disorders, motor disorders, tic disorders and 
other/unspecified ND. 
2.2.1.1 ASD 
The co-occurrence of ADHD and ASD has received increased attention during the last 
decade.4,58-64 ASD is a group of neurodevelopmental disorders affecting 1-2% of the general 
population65-67 and it is characterized by impairments in social interaction and communication 
and by the presence of repetitive and stereotyped patterns of behaviours, interests and 
activities.1,2 Although ADHD and ASD do not appear to share a lot in terms of core symptoms, 
these NDs have some important features in common. ASD symptoms, similarly to ADHD 
symptoms, seem to represent the extreme end of traits that are normally distributed in the 
population.68,69 In addition, alike ADHD, ASD is highly heritable70 and more prevalent in 
males than in females.65-67 
Several studies have reported that children and adolescents diagnosed with ADHD may display 
autistic symptoms.4,58-61 Likewise, symptoms of ADHD are common among children and 
adolescents diagnosed with ASD.62-64 In a community sample from the United Kingdom, a 
standardized interview was used to evaluate the rates of psychiatric disorders based on DSM-
IV symptoms in children with ASD. It was found that 70% of the sample met criteria for at 
least one other disorder listed by DSM-IV and ADHD was among the most common, with a 
point estimate for the prevalence slightly below 30%.64 It is noteworthy to mention that DSM-
IV and ICD-10 did not allow diagnosing ADHD in children with ASD. However, this has 
changed with DSM-5. In fact, in the fifth version of DSM, ASD is no longer an exclusionary 
diagnosis for ADHD.  
2.3 AETIOLOGY OF ADHD 
ADHD aetiology is multifactorial, and a complex interplay between several genetic and non-
genetic factors is probably implicated. The heritability of ADHD has been repeatedly estimated 
to be between 70 and 90% in large twin and family studies.71-74 Heritability refers to the 
proportion of variation in the liability to ADHD in the population attributable to genetic 
variation (see section 5.2.2). A substantial proportion of this quantity is accounted for by 
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common genetic variants, commonly known as single nucleotide polymorphisms (SNPs; see 
section 2.6.4), each of which has a very small effect.75,76 In a large study including several 
population-based samples, SNP-based heritability for ADHD symptom scores was estimated 
to be between 5 and 34%.76 In addition, a meta-analysis of genome-wide association studies 
(GWAS; see section 2.6.4), which included over 20,000 individuals diagnosed with ADHD 
and over 35,000 controls, has recently identified the first 12 genome-wide significant risk loci 
associated with ADHD and calculated a SNP-based heritability for ADHD around 22%.75  
Furthermore, it has been shown that the risk alleles for ADHD discovered in GWAS, which 
were based on case-control comparison, also contribute to individual differences in the general 
population in traits that are related to symptoms of hyperactivity, impulsivity, and 
inattentiveness.75-77 Therefore, it seems that overlapping genetic factors may contribute to both 
continuous variations of ADHD symptoms in the general population and dichotomous 
measures of ADHD, that is, the clinically diagnosed cases vs controls. 
Several studies have reported associations between environmental factors and ADHD, 
including pre- and postnatal factors, environmental toxins, diet and psychosocial adversities.78-
80 However, only a few studies have attempted to examine whether these associations may be 
consistent with a causal hypothesis or primarily due to unmeasured familial confounders. For 
example, there is some evidence that the association between paternal age at childbearing,81 
family income,82 and low-birth weight83,84 and ADHD may be consistent with a causal 
interpretation. On the contrary, the association between maternal smoking during pregnancy 
and offspring ADHD85,86 seems to be explained by shared familial confounding, that is, factors 
shared between the mother and the offspring that predispose the mother to smoke and the child 
to develop ADHD (see sections 2.6.1 and 2.6.2 on causal inference and confounding).87-89  
2.3.1 Shared aetiology between ADHD and ASD 
Based on the observation that individuals diagnosed with ADHD also tend to display symptoms 
of ASD and vice versa, several twin studies have evaluated the relative importance of genetic 
and environmental factors for the overlap between traits related to ADHD and ASD.90-94 
Although moderate genetic correlations between traits related to ADHD and ASD have been 
reported by several studies, the genetic overlap between clinically ascertained cases of ADHD 
and ASD remains largely unclear.  
The familial transmission of the disorders has been investigated in large samples from the 
general population. One study found that offspring of mothers with clinically diagnosed ADHD 
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were at increased risk of ASD.95 Similarly, a more recent study found an increased risk of 
ADHD in siblings of ASD cases.96  
A GWAS on ASD published earlier this year has reported for the first time a positive genetic 
correlation between ADHD and ASD (around 0.36),97 while previous studies had failed to 
detect a genetic correlation between the disorders.98 Other studies have found an overlap 
between ADHD and ASD in rare chromosomal deletions and duplications.99,100 
2.4 ADVERSE OUTCOMES OF ADHD 
Individuals diagnosed with ADHD suffer from impairments in several aspects of their 
functioning. During childhood and adolescence, they are more likely to experience problems 
in social and school functioning101,102 and to be bullied.103,104 Furthermore, they are less likely 
to complete high school and continue toward post-secondary education.9,105,106 As adults, they 
are more likely to struggle with work and social environment.9,37,50,52,106,107 Moreover, ADHD 
is associated with a higher risk of substance abuse,108-110 criminality,12,111,112  victimization,113-
115 different types of injuries,116-120 and suicide.10,121,122 
Despite the high rate of comorbidity between ADHD and other NDs and the link between 
ADHD and several negative outcomes are well documented, it remains unclear if and how 
comorbidity with NDs may influence the risk of these negative outcomes, which may be 
specifically related to ADHD or, more generally, to the broader diagnostic group of NDs. 
 
2.5 TREATMENT OF ADHD 
According to the European clinical guidelines, the management of ADHD symptoms involves 
several types of interventions, including “psychological interventions, educational change, 
medication and diet”, which should be optimally combined into a multimodal approach.22 
These guidelines define a treatment hierarchy, which recommends the use of medication when 
“psychological treatments are insufficient alone” or in the most severely disabled cases.22 
2.5.1 Non-pharmacological treatment of ADHD 
When diagnosed with ADHD, patients and their families should be informed about how ADHD 
symptoms may impact their life and how to identify and further develop strengths in the 
patients and in their families. Several simple changes in the environment or routines may help 
improving ADHD symptoms. Other non-pharmacological approaches for the management of 
ADHD symptoms include group- or individual-based behavioural interventions at the family 
level, such as parent-training programmes. Schools may also be involved (for school-aged 
children). For pre-school children, interventions are mainly directed to parents or carers. 
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Cognitive-behavioural therapy is usually offered to older children who have benefitted from 
medication, but may have residual symptoms that cause some level of impairment. Among 
adults, psychosocial interventions are recommended in case of reduced adherence to 
medication, due to ineffectiveness or poor toleration, or in the case of informed decision to 
decline medications.22,23   
2.5.2 Pharmacological treatment of ADHD 
Stimulants are the main type of medication approved and used for the management of ADHD 
symptoms. European guidelines recommend methylphenidate as the first drug of choice.22 
Other stimulant medications commonly used in European countries are dexamfetamine and 
pemoline.22 Non-stimulant medications (for example atomoxetine) have also been used to treat 
ADHD, although their efficacy seems to be inferior to stimulants.123 
Findings from RCTs indicate that these medications have beneficial short-term effects on the 
core symptoms of ADHD and may lead to improvements in several functional domains.14,123,124 
Likewise, observational studies have found that ADHD medication use is associated with 
reduced risk of adverse outcomes.125-133 A recent meta-analysis of observational studies has 
reported an increased risk of different types of injuries among individuals with ADHD and a 
lower risk of injuries in association with use of ADHD medication.134 Unintentional injuries, 
such as traffic accidents, falls and poisoning, represent a leading cause of disability in 
Europe.135,136 Therefore, it is clinically important to understand whether pharmacological 
treatment of ADHD symptoms, may also help to reduce the occurrence of adverse health 
outcomes associated with ADHD.   
2.5.3 Pharmacological treatment of ADHD in the context of other NDs 
Although there is consistent evidence indicating general safety and efficacy of pharmacological 
interventions from RCTs and meta-analyses, less is known about their effect in ADHD patients 
with other NDs. For example, in the case of co-occurrence of ADHD and ASD, guidelines 
recommend the use of methylphenidate and cognitive-behavioural therapy in combination,22 
however, very few studies have directly evaluated safety and efficacy of such interventions 
among individuals with both ADHD and ASD.137 In addition, despite the increasing evidence 
from observational studies showing that ADHD medication use is associated with a decreased 
risk of several adverse outcomes, no previous study has explored whether the association may 
be different among those with other NDs. For example, Man and colleagues investigated the 
association between methylphenidate use and risk of trauma in a large population-based cohort 
and found that methylphenidate use was associated with a lower risk of trauma. In the study, it 
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was reported that over 12% of the sample had been diagnosed with ASD and a similar 
proportion had been diagnosed with specific developmental delays. However, the authors did 
not provide separate estimates for groups with different diagnoses.130    
2.6 AN EPIDEMIOLOGICAL APPROACH  
Classic epidemiologic research deals with the distribution of diseases and other health states in 
the population, their predictors and their consequences.138 On a more descriptive level, 
epidemiological studies can estimate prevalence or incidence of diseases and compare them 
across groups and populations, or describe time trends. Epidemiology often focuses on 
identifying causes of diseases or factors that may prevent them, that is, rather than describing 
patterns of diseases, the aim is to understand the mechanisms underlying diseases. For instance, 
in psychiatry, epidemiological studies have addressed crucial questions on the role of 
demographic characteristics and environmental exposures in influencing the risk of a disorder, 
or if certain disorders tend to cluster in families, or which genetic variants are associated with 
one or more disorders.139 Other epidemiological studies focus on the evaluation of treatment or 
prevention strategies on one or several outcomes, including, for example, risks, benefits and 
costs.    
2.6.1 Causal inference in epidemiology 
Ideally, evaluation of the causal effect of an exposure on an outcome would require observing 
the outcome of each study participant under the different levels of the exposure at the same 
time. In other words, in the simple case of an exposure that has only two possible levels (that 
is, a person is either exposed or unexposed), the best test to establish whether there is a causal 
relationship between an exposure and an outcome would be the comparison between the 
outcome of a study participant exposed vs the outcome of the same study participant, had this 
person not been exposed. The latter scenario is often referred to as the counterfactual outcome, 
as it is not observable. However, if it were possible to observe and measure both outcomes for 
each subject (that is, the outcome when exposed and the outcome when unexposed), the 
exposure effect for each individual could be easily calculated by contrasting these quantities.140 
In RCTs, random allocation of study participants to the different levels of the exposure of 
interest ensures that exposure does not depend on observed or unobserved characteristics. 
Random allocation tends to create groups that are, on average, comparable in terms of 
background characteristics. In other words, randomization ensures sufficient exchangeability 
between different exposure groups. Therefore, in RCTs the effect of an exposure can be 
estimated by comparing outcomes between exposed and unexposed.141  
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Causality often has to be inferred from observational data, that is, data obtained without any 
manipulation of the allocation of the exposure. This is because random assignment of 
individuals to certain exposures may not always be feasible or ethical, as in the case of 
exposures that have already been established as risk factors for human health. In observational 
studies, the lack of randomization may lead to systematic differences between exposed and 
unexposed individuals. In fact, the probability of being exposed or unexposed to a certain factor 
may be influenced by several observable or unobservable characteristics, which may also be 
related to the outcome under study. Consequently, a major challenge in observational studies 
is to remove the effect of these observable and unobservable differences between exposed and 
unexposed, in order to estimate the causal effect of the exposure on the outcome. In fact, when 
a factor influences both the probability of having a certain level of the exposure and the 
probability of having the outcome of interest, it creates an association between the exposure 
and the outcome, which is not due to their causal relationship. Such factor is referred to as a 
confounder. A confounder may be defined as any variable U, influencing both the exposure 
and the outcome, but not being on the causal path going from the exposure to the outcome.138 
An illustration of confounding is given in the Directed acyclic graph (DAG) depicted in Figure 
2.6.1. 
                                                                    U 
                                                   X                              Y 
Figure 2.6.1 DAG illustrating confounding. The DAG illustrates that U is a confounder, because it influences 
the exposure X and the outcome Y and is not on the causal path going from the exposure X to the outcome Y. 
Because of the causal relationship of U with both X and Y, U induces an association between X and Y, even if 
there is no direct causal relationship between X and Y. 
Traditionally, confounding in observational studies has been addressed by controlling for those 
variables that are known to influence both the exposure and the outcome and that can be 
measured. Controlling for a confounder often implies adjusting for it in a statistical model or 
matching the groups who are compared on the relevant confounders. However, sometimes 
there might be relevant confounders that researchers are unaware of or that are not easily 
measurable. An example of such factors are genetic influences on human traits and diseases, 
which are often unknown or unmeasured.  
2.6.2 Causation in genetically informative studies  
Genetic influences can often represent confounders for a putative causal relationship of interest. 
This phenomenon is commonly referred to as genetic confounding. For example, if the genetic 
factors that influence the risk of ADHD also influence the risk of being victimized,142 such 
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genetic overlap will induce a spurious association between ADHD and risk of victimization. 
An illustration of this phenomenon is given in the DAG depicted in Figure 2.6.2. 
                                                                    G 
                                          ADHD                               VICTIMIZATION 
Figure 2.6.2 DAG illustrating genetic confounding. The DAG illustrates that G, genetic influences, is a 
confounder, because it influences the exposure ADHD and the outcome VICTIMIZATION and is not on the causal 
path going from ADHD to VICTIMIZATION. Because of the causal relationship of G with both ADHD and 
VICTIMIZATION, G induces an association between ADHD and VCTIMIZATION, although there is no direct 
causal relationship between ADHD and VICTIMIZATION. 
One way to assess and adjust for genetic confounding, when data on measured genetic markers 
are not available, is to use of information on individuals who are genetically related. For 
example, sibling-comparison design is a type of genetically informative design in which 
unmeasured potential confounders that are shared by memebrs of a cluster of siblings, 
including genetic and non gentic factors,  are adjusted for. Of note, sibling-comparison design 
can adjust for only part of the potential genetic confounding, as siblings are not genetically 
identical, but it can adjust for other non-genetic factors that are shared by siblings and that may 
be relevant confounders.  A special case of genetically informative design that attempts to 
control for unmeasured potential confounders in order to ask a causal question, is the within-
individual comparison. In this type of study the aim is to adjust for all the background 
characteristics of an individual, including genetic and non-genetic factors that are stable within 
the person. These approaches will be described in section 5.1.3. 
2.6.3 Quantitative genetic studies 
Information on individuals who are genetically related may also be used to examine the relative 
importance of genetic and environmental influences on human traits and diseases or on the 
potential overlap between traits and diseases. For example, familial co-aggregation studies and 
twin studies take advantage of the different degree of sharing of genetic and environmental 
factors between different types of biological relatives in order to better understand the role of 
such factors in causing a disorder. Familial co-aggregation studies and twin studies will be 
described in sections 5.1.1 and 5.1.2. 
2.6.4 The role of genomics in epidemiology 
In the last fifteen years, genomic research has provided new tools to explore the role of genetic 
factors in the aetiology of human traits and diseases. Since the first GWAS in 2005,143 
thousands of loci have been reported in association with traits and disorders.144 In addition to 
that, summary statistics from GWAS have been used to calculate the so-called genome-wide 
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polygenic scores. These measures correspond to the aggregated effect of all the SNPs 
associated with the phenotype under study.145 Therefore, these scores represent a way to 
measure genetic liability to a trait or a disorder, without having information on related 
individuals. Genome-wide polygenic scores may be used to explore associations across 
phenotypes, similarly to family and twin studies. In addition, if the polygenic scores were good 
predictors of a phenotype, they could be used as proxies for phenotypes that have not been 
measured, but that may be an important confounder.  
In general, genetic information is becoming an integrated part of observational studies.146 It 
may come from measured genetic markers or it may be inferred from familial relationships. It 
may shed light on the relative importance of genetic and non-genetic factors for a phenotype 
or for the covariation between phenotypes. It may also help to identify causal mechanisms 
behind observed associations. As each approach makes different assumptions and has inherent 
limitations and advantages, convergence from studies using different designs is a crucial goal 
to advance the understanding of diseases’ causes and consequences.147,148  
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3 AIMS 
3.1 OVERARCHING AIM 
The overarching aim of this thesis is to extend previous knowledge about the comorbidity 
between ADHD, ASD and other neurodevelopmental disorders, focusing on possible shared 
aetiology, treatment effectiveness and adverse health consequences. 
3.2 SPECIFIC AIMS 
 To evaluate to what extent ADHD and ASD may be caused by shared and specific 
aetiological factors (Study 1 & 2). 
 To examine the impact of ADHD, other NDs and ADHD medication on health adverse 
outcomes. (Study 3 & 4).  
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4 DATA AND MEASURES 
Studies 1, 3, and 4 were all based on data derived from a linkage of several Swedish nationwide 
registers. Study 2 included data from the Young Adult Twin Study in Sweden (YATSS).  
4.1 SWEDISH NATIONAL REGISTERS 
The personal identity number (PIN)149 consists of the date of birth and a four-digit number and 
was introduced in Sweden in 1947 (the fourth digit was added in 1967). Therefore, since then, 
every person residing in Sweden on a permanent basis (that is, recorded in the Total population 
register, TPR) is assigned a PIN. The PIN is routinely used by governmental agencies (e.g., tax 
agency, health care providers, prison services, schools, etc.). Governmental agencies (such as 
Statistics Sweden) can merge data from different registers using the PIN. The following 
nationwide registers were the main sources of data for the present thesis. 
Total population register (TPR). TPR includes information on demographics (date of birth, 
sex, country of birth, migration, date of death) on all individuals residing in Sweden who were 
born after 1932 and were alive in 1968 or later.150 
Multi-generation register (MGR). MGR provides information on biological (and, when 
applicable, adoptive) parents of all individuals born after 1932, alive and living in Sweden after 
1961, with the exception of those whose parents died or migrated out of the country before 
1947.151 For individuals born since 1950 information on mothers is complete while the 
coverage of information on fathers is slightly lower.  
National patient register (NPR). NPR contains information on all in-patient care in Sweden 
from 1987 and on outpatient visits from 2001.152 Data from primary care are not included in 
the NPR. When the register was started by the National Board of Health and Welfare in the 
1960’s, it only contained information about patients treated in psychiatric care and a small 
proportion of patients in somatic care. The diagnoses in the NPR are classified according to the 
International Classification of Diseases; ICD-8 (1969-1986), ICD-9 (1987-1996) and ICD-10 
(1997-2013). 
Medical birth register (MBR). The MBR includes information on a wide range of pre-, peri- 
and post-natal factors of nearly all births in Sweden since 1973. It also includes information on 
several measures about the mothers.153 
Prescribed drug register (PDR). The PDR includes information on all dispensed prescribed 
drugs in Sweden since June 1st 2005.154 All medicines are classified according to the 
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Anatomical Therapeutics Chemical (ATC) classification system. The PDR does not include 
information on drugs used in hospitals or on the indication for treatment.  
Longitudinal integration database for health insurance and labour market studies register 
(LISA). The LISA register includes data on all individuals aged 16 or older registered in 
Sweden as of December 31st of each year since 1990. It covers information on marital status, 
residential relocations, educational attainment, income, unemployment, and social 
benefits.155,156 
National crime register (NCR). The NCR contains records of all criminal convictions in 
Swedish lower courts since 1973, including non-custodial sentences and fines. The legal age 
of responsibility in Sweden is 15 years, so no data on criminal convictions for individuals 
younger than this age are available.157,158 
Cause of death register (CDR). The CDR provides information on all deaths among individuals 
registered in Sweden from 1952.159 The CDR does not include information on stillbirths, 
individuals who died on a temporary visit to Sweden, asylum seekers without residence permit 
and Swedish citizens who have emigrated and are not registered in Sweden. Underlying causes 
of death are coded according to ICD classification system.  
Swedish twin registry (STR). The STR was established in 1959 and contains information on 
approximately 200,000 twins born in Sweden after 1886.160-162 The register is managed by 
Karolinska Institutet. Currently, twins are invited to be part of the register when they turn nine. 
In addition to information on zygosity, information from surveys and from collection of 
biological samples are available for several cohorts of twins. 
4.1.1 Main measures in the registers 
4.1.1.1 ADHD  
There are two main sources of information on ADHD in the registers. First, the presence of a 
diagnosis in the NPR according to ICD classification system can be used to identify individuals 
who were ever diagnosed with HKD. To define ADHD, we used the ICD-9 code 314 
(“Hyperkinetic syndrome of childhood”) and the ICD-10 code F90 (“Hyperkinetic 
disorders”).163 Second, it is possible to identify all dispensed medications approved in Sweden 
for the management of ADHD from the PDR.158 The following medications were approved in 
Sweden for the management of ADHD during the time period relevant for the studies included 
this thesis (ATC codes in parentheses): Methylphenidate (N06BA04); Amphetamine 
(N06BA01); Dexamphetamine (N06BA02); Lisdexamfetamin (N06BA12); Atomoxetine 
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(N06BA09). Information on ADHD from the NPR was used in all the studies. In Study 1, 
information on ADHD medication from the PDR was additionally used to define ADHD cases.     
4.1.1.2 ASD 
In order to identify individuals with ASD, information from the NPR was used. The ICD-9 
code 299 (“Pervasive developmental disorders”) and the ICD-10 code F84 (“Pervasive 
developmental disorders”) were used to identify individuals with ASD.66,164 This information 
was used in all the studies. Furthermore, information from the NPR on diagnoses of ID 
according to ICD-9 (codes 317-319) and ICD-10 (codes F70-F79) was used in Study 1 to 
identify individuals with ASD and ID, which was defined as low-functioning ASD, vs ASD 
without ID, which was defined as high-functioning ASD. 
4.1.1.3 Other NDs 
Information from the NPR was used to define other NDs in Study 3 and in Study 4. We grouped 
NDs similarly to the classification proposed by DSM-5. In addition to ADHD and ASD, other 
NDs were: ID, communication disorders, specific learning disorder, motor disorders, and 
other/unspecified neurodevelopmental disorders. A complete list of all the ICD-9 and ICD-10 
codes used for NDs can be found in Table 4.1.1.3. These diagnoses were used to define NDs 
in Study 3 and in Study 4.  
Table 4.1.1.3 ICD Codes for NDs. Abbreviations: NDs=neurodevelopmental disorders; DSM-5=Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition; ICD-9=The International Classification of Diseases, Ninth 
Revision; ICD-10=The International Classification of Diseases, Tenth Revision. 
4.1.1.4 Treatment status by ADHD medication 
In Study 3, we used information from the PDR on all medications approved in Sweden for the 
management of ADHD during the study period (January 1st 2006 – December 31st 2013). Based 
on dispensations of these medications, we divided the study period into on-treatment and off-
treatment periods. Prescriptions for ADHD medication are usually refilled within 3 months. In 
the case of low adherence or treatment cessation during weekends or holiday, time between 
dispensations may be longer. Consequently, on-treatment periods were defined as the time 
between two consecutive medication dispensations that were no longer than 122 days apart 
(122-days interval), similarly to previous studies.112,127,165,166 On-treatment periods started with 
Disorders ICD-9 codes ICD-10 codes 
ADHD 314 F90 
ASD 299 F84 
ID  317-319  F70-F79 
Communication disorders 315.3 F80 
Specific learning disorder 315.0, 315.1,315.2 F81, R48 
Motor disorders  315.4, 307.2, 307.3 F82,  F95, F984 
Other neurodevelopmental disorders 315.8, 315.9 F88-F89 
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the first dispensation date and ended with the last dispensation date. The remaining follow-up 
time was defined as off-treatment.   
4.1.1.5 Unintentional injuries 
Information from the NPR was used to identify unintentional injuries. Unintentional injuries 
were defined as inpatient and outpatient visits reporting an injury as the main diagnosis (ICD-
10 codes: S00-T78) and an unintentional cause (ICD-10 codes: V01-X59). This definition was 
used for the outcome of Study 3. Moreover, because there was a concern that the same injury 
may be recorded several times, as the same injury may be associated with several visits, we 
only included unplanned visits longer than 14 days apart to reduce the risk to count the same 
event multiple times.  
4.1.1.6 Violent victimization 
Information from the NPR and the CDR was used to identify violent victimization events. 
Violent victimization events were defined as any inpatient visit, outpatient visit or death 
reporting assault as cause (ICD-9 codes: E960-E969; ICD-10 codes: X85-Y09). Violent 
victimization was the outcome in Study 4.  
4.2 YATSS 
Study 2 was based on the Young Adult Twin Study in Sweden (YATSS). The survey was 
initiated in 2013. Using information from the STR, approximately 17,000 twins born in Sweden 
between May 1st 1985 and June 30th 1992 were identified. Individuals who had opted out of 
the STR, died, migrated, or acquired a secret identity were excluded. Individuals who were 
invited to participate in the study (N=16,237) were asked to fill out an online questionnaire. A 
paper version was available upon request. Seven individuals who had requested to be re-
included in the STR were included at a later stage. The final target population included 16,244 
individuals. Among them, 6,866 (42%) filled out the questionnaire, either the on-line or the 
paper version. Among them, the response rate for all the ADHD and ASD traits was 74% 
(N=5,082). Information on zygosity was obtained using a set of physical similarity questions, 
which has been validated through genotyping. 
4.2.1 Measures of ADHD and ASD trait dimensions in YATSS 
In Study 2, the focus was on ADHD and ASD trait dimensions, which were self-reported by 
study participants. ADHD trait dimensions were assessed via the WHO Adult ADHD Self-
Report Scale (ASRS).31,167 This questionnaire consists of 18 items that resemble DSM-IV 
symptoms. Each item has a five-point answer format (0=‘never’, 1=‘rarely’, 2=‘sometimes’, 
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3=‘often’ and 4=‘very often’). Answers to each items were summed in order to create two 
scores reflecting the two symptom-dimensions of ADHD: inattention (IA, nine items), and 
hyperactivity/impulsivity (HI, nine items). ASD trait dimensions were assessed via a set of 12 
items, which are part of the Autism – Tics, AD/HD, and other Comorbidities inventory (A-
TAC).168 The items are based on DSM-IV symptoms. A-TAC has been developed for 
assessment of a wide range of behaviours, cognitive domains and psychiatric symptoms in 
children. Therefore, some of the items were adapted for adults. Each item has a three-point 
answer format (0=‘no’, 0.5=‘yes, to some extent’, and 1=‘yes’). Answers to each item were 
summed to create two scores reflecting the two symptom-dimensions of ASD, based on DSM-
5 classification: social interaction and communication difficulties (SIC, eight items), and 
repetitive and restricted behaviours (RRB, four items). A complete list of the items used in 
Study 2 is reported in Table 4.2.1. 
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Table 4.2.1 List of items used to assess ADHD and ASD traits. The table reports the English translation of the 
items used to assess ADHD and ASD trait dimensions in YATSS. Abbreviations: IA=inattention; 
HI=hyperactivity/impulsivity; RRB=repetitive and restricted behaviours; SIC=social interaction and 
communication difficulties. 
  
Items  Subscale  
How often do you have trouble wrapping up the final details of a project, once the 
challenging parts have been done?  
IA  
How often do you have difficulty getting things in order when you have to do a task that 
requires organization?  
IA  
How often do you have problems remembering appointments or obligations?  IA  
When you have a task that requires a lot of thought, how often do you avoid or delay getting 
started?  
IA  
How often do you fidget or squirm with your hands or feet when you have to sit down for a 
long time?  
HI  
How often do you feel overly active and compelled to do things, like you were driven by a 
motor?  
HI  
How often do you make careless mistakes when you have to work on a boring or difficult 
project?  
IA  
How often do you have difficulty keeping your attention when you are doing boring or 
repetitive work?  
IA  
How often do you have difficulty concentrating on what people say to you, even when they 
are speaking to you directly?  
IA  
How often do you misplace or have difficulty finding things at home or at work?  IA  
How often are you distracted by activity or noise around you?  IA  
How often do you leave your seat in meetings or other situations in which you are expected 
to remain seated?  
HI  
How often do you feel restless or fidgety?  HI  
How often do you have difficulty unwinding and relaxing when you have time for yourself?  HI  
How often do you find yourself talking too much when you are in social situations?  HI  
When you are in a conversation, how often do you find yourself finishing the sentences of 
the people you are talking to, before they can finish themselves?  
HI  
How often do you have difficulty waiting your turn in situations when turn taking is 
required?  
HI  
How often do you interrupt others when they are busy?  HI  
Do you have difficulties expressing emotions and reactions with facial gestures, 
pronunciation, or body language?  
SIC  
Have you difficulties to get and keep friends?  SIC  
Are you disinterested in sharing joy, interests, and activities with others?  SIC  
Can you only be with other people on your terms?  SIC  
Was your language development delayed?  SIC  
Do you have difficulties participating in discussions with others?  SIC  
Do you like to repeat words and expressions or do you use words in a way other people find 
strange?  
SIC  
Do you have difficulty imitating other people or to play charades?  SIC  
Do you get absorbed by your interests in such a way as being repetitive or too intense?  RRB  
Do you get absorbed by routines in such a way as to produce problems for yourself or for 
others?  
RRB  
Have you some body movements that come automatically when you are happy or upset?  RRB  
Do you get absorbed by details?  RRB  
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5 METHODS 
5.1 STUDY DESIGNS 
5.1.1 Familial co-aggregation studies 
Familial aggregation studies often represent the first step to understand if familial influences 
(of genetic and non-genetic origin) have a role in the occurrence of one disorder or in the co-
occurrence of two or more disorders.169,170 Family members share a higher amount of genetic 
and environmental factors as compared to unrelated individuals. Consequently, whenever a 
disorder is more common among relatives of individuals who have the disorder as compared 
to relatives of individuals who do not have the disorder, genetic and environmental factors 
shared by family members may be assumed to play a role in the aetiology of the disorder. 
Similarly, whenever a disorder A is more common among relatives of individuals who have 
the disorder B as compared to relatives of individuals who do not have the disorder B, genetic 
and environmental factors shared by family members may be assumed to play a role in the 
aetiology of the co-occurrence of the disorders A and B.  
In addition, it is possible to compare the magnitude of the association across different types of 
relatives in order to assess the importance of genetic and non-genetic factors that influence 
familial co-aggregation. For example, it is possible to compare the association of two disorders 
in full siblings, who share on average 50% of their co-segregating alleles, with the association 
of two disorders in half siblings, who share on average 25% of their co-segregating alleles. A 
higher association among full siblings compared to half siblings provides evidence for the 
importance of genetic influences. However, it should be noted that different types of relatives 
might share other non-genetic influences to a different extent. For example, it may be assumed 
that maternal half siblings share more pre-natal environmental factors than paternal half 
siblings, as there will be more similarities between two different pregnancies in the same 
woman than between two pregnancies in different women.  
5.1.2 Twin studies 
Twin study design capitalizes on the comparison of the resemblance on a trait between 
monozygotic (MZ) and dizygotic (DZ) twins.171 The difference between MZ and DZ twins is 
that MZ twins are genetically identical, while DZ twins share, on average, half of their co-
segregating alleles, just like full siblings. Furthermore, it is assumed that MZ and DZ twins 
share the same amount of common environmental influences. For this reason, by using 
information on the degree of resemblance between members of MZ twin pairs on a certain trait 
vs the degree of resemblance between members of DZ twin pairs on the same trait, it is possible 
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to understand whether genetic influence may be important for such trait or not. In other words, 
if a trait is influenced by genetics, the correlation between the members of a twin pair on this 
trait (usually referred to as intra-class correlation, ICC) is expected to be greater in MZ than in 
DZ twins. Similarly, it is possible to examine cross-trait correlations to understand the relative 
importance of genetic and environmental influences for the covariation between two traits. To 
this purpose, a correlation between trait A for twin 1 and trait B in twin 2 (usually referred to 
as cross-twin cross-trait correlations, CTCT) is calculated in MZ and DZ twin pairs separately 
and CTCT correlations are then contrasted. Higher CTCT correlations among MZ twins than 
among DZ twins indicate that the covariation between the traits under study is influenced by 
overlapping genetic effects. In Study 2, information on ADHD and ASD trait dimensions 
reported by MZ and DZ twins was used to decompose the observed variation and covariation 
of such traits into the genetic and non-genetic influences. Structural equation modelling (SEM) 
was used to estimate the contribution of these influences.172 A description this method is given 
in section 5.2.2. 
5.1.3 Within-cluster comparison 
A common strategy to adjust for confounding in observational studies is to match on one or 
several potential confounders. For example, in cohort studies, it is possible to select a number 
of unexposed individuals with the same level of the covariate(s) that we want to adjust for as 
the exposed individuals. By doing so, the association between the potential confounder(s) and 
the exposure is broken. In other words, matching ensures that exposed and unexposed are 
conditionally exchangeable. Similarly, in case-control studies, controls can be selected so that 
they are matched to cases on the level of covariate(s) that we want to adjust for.  
Matching occurs naturally in a number of instances. For example, members of a MZ twin pair 
are matched on virtually all their genetic background and pre-natal environment. Thus, by 
comparing the members of a MZ twin pair where one member experiences a certain exposure 
and the other does not, the association between the aforementioned potential confounders and 
the exposure of interest is broken. In other words, comparing differentially exposed members 
of a cluster allows for matching for all the factors that members of a cluster share, without the 
need of measuring such factors, and, therefore, it approximates conditional exchangeability 
within the cluster.  
5.1.3.1 Within-sibling comparison 
In a within-sibling comparison study, members of clusters of siblings, who are differentially 
exposed to a risk (or protective) factor, are compared in terms of the outcome(s) of interest. In 
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this way, sibling-comparison design adjusts for all the sources of confounding that are shared 
between siblings.80,173 For example, in full siblings, such comparison will be adjusted for half 
of their genetic make-up, since full siblings share, on average, 50% of their co-segregating 
alleles, and for those environmental exposures shared by siblings, such as parental education 
level or medical history. In Study 4, sibling-comparison design was used to test whether a 
member of a sibling pair who was diagnosed with NDs had a different risk of violent 
victimization compared to a member of the same sibling pair who was not diagnosed with NDs. 
This was done in order to adjust for shared familial factors that may be associated with risk of 
being diagnosed with NDs and with risk of being victimized. 
5.1.3.2 Within-individual comparison 
Within-individual comparison is a special case of within-cluster comparison, in which the same 
individual is compared to him- or her-self under two different levels of the exposure.174 As a 
consequence, this design requires at least two measurements of the exposure for an individual 
to contribute to the analysis. This type of comparison adjusts for all the factors that do not 
change within the same person during the time of the study, such as the genetic background or 
previous experiences. In Study 3, within-individual comparison design was used to estimate 
the association between ADHD medication use and unintentional injuries by comparing the 
rate of unintentional injuries during periods on-medication with the rate of unintentional 
injuries during periods off-medication within the same person.  
5.2 STATISTICAL METHODS 
5.2.1 Logistic regression 
Logistic regression is a statistical method commonly used to analyze binary outcomes. This 
method allows for estimating the change in the log-odds of the outcome for every unit increase 
in the exposure variable, while controlling for a set of covariates. The measure of association 
between the exposure and the outcome is given by the odds ratio. Odds are defined as the ratio 
of the probability of an event divided by the probability of that event not occurring. An odds 
ratio is the ratio between odds of the event under study in the two different groups that are 
compared. Logistic regression was used in Study 1 to estimate the association between a 
diagnosis of ASD and a diagnosis of ADHD within the same person and within families. 
5.2.2 Structural equation modelling 
Structural equation modelling (SEM) is an approach that incorporates and combines statistical 
methods that can be expressed as models of covariance matrices. SEM is commonly used to 
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estimate the relative contribution of unobserved constructs (traditionally referred to as latent 
variables) in explaining the variance of observable variables or their covariance.172  
SEM is used in quantitative genetics to estimate the contribution of the latent components: 
additive genetic influences (A); environmental influences shared by the members of the twin 
pair (C); dominance genetic effects (D); and other sources of variation that make members of 
a twin pair less similar (E), including non-shared environmental influences and random error. 
A univariate model allows to estimate the contribution of A, C, D, E to the total variance of a 
phenotype. The univariate model can be written as: 
Xi = µ + Ai + Ci + Di + Ei 
where Xi is the observed trait in the i
th individuals in the population and µ is the population 
mean. Assuming that latent components are independent of each other, the variance in a trait 
is defined as: 
Var(X) = Var(A) + Var(C) + Var(D) + Var(E) 
It follows that, in order to estimate the relative contribution of each component to the variance 
of the trait in the population, the ratio between the variance of that component and the total 
variance of the observed trait is taken. For example, the contribution of additive genetics, 
usually referred to as narrow-sense heritability (h2), is given by: 
h2= Var(A)/Var(X) 
It should be noted that it is not possible to estimate the C and the D components simultaneously, 
together with A and E components, when only data from twin pairs are available. In other 
words, the information from MZ and DZ twins is not sufficient to estimate all the parameters 
in the model. Usually an ADE model (that is, a model including A, D, and E as sources of 
variance and covariance) and ACE model (that is, a model including A, C, and E as sources of 
variance and covariance) can only be fitted to the data separately and then compared in order 
to establish which one fits the data better. 
In a multivariate model, it is possible to estimate the contribution of each of these latent 
components to the total variance of more than one phenotype as well as to the covariance 
between the phenotypes.  A multivariate model was used in Study 2.  
5.2.3 Cox regression 
Cox regression is a statistical method commonly used to analyze time-to-event data. It allows 
for comparing the rate of events between different levels of the exposure of interest while 
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controlling for other covariates included in the model and for the selected underlying time-
scale. The rates in each level of the exposure are hazard rates, which can be thought as 
“instantaneous rates of occurrence”. The hazard function is obtained by, first, calculating the 
ratio between the conditional probability that the event will occur in a certain time interval, 
given that it has not occurred before, and the width of the time interval, and, second, by taking 
the limit as the width of the interval goes down to zero. The hazard ratio (HR) is then given by 
the ratio between the hazard functions under the different levels of the exposure.  
5.2.3.1 Stratified Cox regression model 
When data are clustered, within individuals as in Study 3 or within families as in Study 4, it is 
possible to exploit the structure of the data to adjust for factors that are shared across different 
observations within the cluster.175 Stratified Cox regression can be used to compare the hazards 
across different levels of the exposure within the same cluster (also referred to as stratum). In 
this model, the coefficients of the different levels of the exposure are the same for each stratum, 
while the baseline hazards (i.e., the hazard for the baseline level of the exposure) are free to 
differ across strata.  
In Study 3, stratified Cox regression was used to compare the hazard between on- and off-
medication periods within the same individual. Each individual is considered as a separate 
stratum and the comparison between exposure categories (on- versus off-medication) is done 
within each stratum. 
In Study 4, stratified Cox regression was used to compare the hazard within each cluster of full 
siblings between a sibling who is diagnosed with NDs and a sibling who is not diagnosed with 
NDs. Thus, each cluster of full siblings is entered in the model as a separate stratum. 
 
 
 
 
 
 
 
 
  25 
6 STUDY SUMMARIES AND RESULTS 
6.1 SHARED AETIOLOGY BETWEEN ADHD AND ASD 
Study 1 and 2 were designed to address the knowledge concerning shared aetiology of ADHD 
and ASD both as clinical diagnoses and as trait dimensions.  
6.1.1 Familial co-aggregation of ASD and ADHD (Study 1) 
6.1.1.1 Rationale 
Previous family studies using data on clinical diagnoses of ADHD and ASD have found an 
increased risk of ASD in offspring of mothers with ADHD,95 and an increased risk of ASD in 
siblings of individuals with ADHD176, and vice versa96. However, no previous study has 
examined the association of these disorders in different types of relatives, who share familial 
factors to a different extent. Therefore, Study 1 aimed at testing whether ASD and ADHD co-
aggregate in families and at examining potential differences between low- and high-functioning 
ASD in the link with ADHD. 
 
Figure 6.1.1.1. Family studies on ADHD and ASD. The figure summarizes results from recent studies on the 
association between clinical diagnoses of ADHD and ASD. Abbreviations: OR=odds ration; RR=risk ratio; 
95%CI=95% confidence interval. Note: In Musser et al., 2014, the OR refers to the risk of being diagnosed with 
ASD in offspring of mothers diagnosed with ADHD, as compared with offspring of mothers not diagnosed with 
ADHD. In Jokiranta-Olkoniemi et al., 2016, the RR refers to the risk of being diagnosed with ADHD in siblings 
of individuals diagnosed with ASD, as compared with siblings of individuals not diagnosed with ASD. In 
Jokiranta-Olkoniemi et al., 2018, the RR refers to the risk of being diagnosed with ASD in siblings of individuals 
diagnosed with ADHD, as compared with siblings of individuals not diagnosed with ADHD. 
6.1.1.2 Methods 
All individuals born in Sweden between 1987 and 2006 were identified from the MBR. After 
exclusion of stillbirths, individuals diagnosed with congenital malformations, individuals who 
died or migrated before their 7th birthday, and individuals who were adopted away or whose 
biological parents were not identifiable, 1,899,654 individuals were included in the study. 
Furthermore, using information from the MGR, each individual included in the study was 
linked to their biological relatives and seven cohorts of different types of relatives were created. 
The following cohorts were included in the study: MZ twins, DZ twins, full siblings, maternal 
half siblings, paternal half siblings, full cousins and half cousins. Information from the NPR 
was used to identify individuals with a diagnosis of ASD (low- and high-functioning), ADHD, 
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or both, at any time between age one for ASD and age three for ADHD and December 31st 
2013. 
 
Figure 6.1.1.2. Timeline Study 1. The figure illustrates the timeline for the main data sources and for the sample 
included in Study 1. Abbreviations: NPR=national patient register; ICD=International Classification of Diseases; 
PDR=prescribed drug register.  
Logistic regression was used to estimate the odds of receiving a diagnosis of ADHD in 
individuals with a diagnosis of ASD, as compared with individuals who did not have a 
diagnosis of ASD, among those included in the study (within-individual association). 
Furthermore, logistic regression was used to estimate the odds of receiving a diagnosis of 
ADHD in relatives of individuals with a diagnosis of ASD, as compared with relatives of 
individuals who did not have a diagnosis of ASD, among those included in the study (within-
family association). This analysis was performed in each cohort of relatives separately. In all 
the analyses, we adjusted for sex and year of birth. Separate estimates for high- and low-
functioning ASD were obtained for within-individual association and within-family 
associations in full siblings and full cousins. All the analyses were performed using Stata 14.0 
(StataCorp., College Station, TX, USA). 
6.1.1.3 Results 
Individuals diagnosed with ASD and their relatives had an increased risk of ADHD, as 
displayed in Figure 6.1.1.3. Within-family associations indicated that MZ twins of individuals 
diagnosed with ASD had an increased risk of having a diagnosis of ADHD (OR=17.77; 95% 
CI=9.80-32.22). The association in MZ twins was higher than the associations in DZ twins 
(OR=4.33; 95% CI=3.21-5.85) and in full siblings (OR=4.59; 95% CI=4.39-4.80), which, in 
turn, were higher than the associations estimated in half siblings. The association in maternal 
half siblings (OR=2.25; 95% CI=2.07-2.43) was higher than the one found in paternal half 
siblings (OR=1.68; 95% CI=1.54-1.84). The risk of having ADHD was increased both in full 
cousins (OR=1.64; 95% CI=1.58-1.71) and half cousins (OR=1.30; 95% CI=1.23-1.38) of 
ASD cases. 
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The magnitude of the association was larger when considering high-functioning ASD both in 
full siblings (OR=4.93; 95% CI=4.70-5.17) and in full cousins (OR=1.68; 95% CI=1.62-1.75), 
as compared to low-functioning ASD (full siblings: OR=1.17; 95% CI=1.03-1.32; full cousins 
(OR=0.93; 95% CI=0.85-1.02).  
 
Figure 6.1.1.3. Within-individual and within-family associations between ASD and ADHD. The plot 
illustrates ORs (diamonds) and 95% CI (bars) expressing the association between ASD and ADHD obtained from 
the within-individual analysis performed in the whole study sample and from the within-family analyses performed 
in the different cohorts of relatives. Abbreviations: OR=odds ratios; 95% CI=95% confidence interval.  
6.1.2 ADHD and ASD trait dimensions in adults (Study 2) 
6.1.2.1 Rationale 
Previous twin studies support the presence of a genetic link between traits related to ADHD 
and traits related to ASD.90,91,177-179 Furthermore, some traits related to ADHD seem to be more 
strongly associated with certain traits related to ASD.94,180,181 However, studies in children94,180 
and in adults181 have led to partially different conclusions. Considering the paucity of studies 
on the link between specific ADHD and ASD traits in adults, Study 2 aimed at estimating 
phenotypic and aetiological overlap between ADHD and ASD trait dimensions in young adults. 
 
Figure 6.1.2.1. Twin studies on ADHD and ASD trait dimensions. The figure reports genetic correlations 
between ADHD and ASD trait dimensions from previous twin studies from childhood to adulthood. 
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Abbreviations: rg=genetic correlation; IA=inattention; HI=hyperactivity/impulsivity; RRB=repetitive and 
restricted behaviours; SIC=social interaction and communication difficulties; C=communication difficulties. 
6.1.2.2 Methods 
First, a saturated model and several sub-models were fitted to the data to obtain age-adjusted 
estimates of means, variances, and correlations, and to perform assumption testing using 
likelihood ratio tests. Then, SEM was used to estimate the phenotypic correlation between IA, 
HI, RRB, SIC, to decompose the observed correlations into genetic and non-genetic 
contributions, and to estimate correlations between genetic and non-genetic factors influencing 
each trait dimension. To examine the relative contribution of A, D, and E to the phenotypic 
correlations between trait dimensions, a model that allowed the sources of variation and 
covariation to correlate between trait dimensions (correlated factors model) was fitted to the 
data. The choice of an ADE model was motivated by the observation that most correlations 
were more than twice as higher in MZ twins than in DZ twins. Potential sex differences were 
investigated in a set of sex-limitation models, which tested for quantitative and qualitative sex 
differences. Quantitative differences refer to differences between males and females in the 
relative importance of each component in influencing correlations, while qualitative 
differences refer to differences between males and females in the sets of genes influencing 
correlations.  
In addition, a set of sub-models (AE and E models) were fitted to the data in order to evaluate 
whether a more parsimonious model would explain the data significantly worse. More 
specifically, comparing the AE model to the ADE model is a way to test whether disregarding 
the influence of D causes a significant loss in the indexes measuring the fit of the model. 
Similarly, the comparison of the E model to the AE model allows testing whether disregarding 
any genetic source of variation/covariation causes a significant loss in the fit of the model. 
Likelihood ratio test and Akaike Information Criterion were reported in order to evaluate the 
fit of the models. All the analyses were conducted using OpenMx.182 
6.1.2.3 Results 
Main results were obtained from the AE model not allowing for sex differences, since this was 
the most parsimonious solution that did not lead to a significant loss in the fit of the model. At 
the phenotypic level, the correlation (rP) between IA and RRB (rP=0.33; 95% CI=0.31-0.36) 
was similar to the one between IA and SIC (rP=0.32; 95% CI=0.29-0.34), while the correlation 
between HI and RRB (rP=0.38; 95% CI=0.35-0.40) was stronger than the one between HI and 
SIC (rP=0.24; 95% CI=0.21-0.26). A and E components accounted for a similar amount of the 
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phenotypic correlations across all trait dimensions under study. Phenotypic correlations and A 
and E contributions are reported in Figure 6.1.2.3. 
 
Figure 6.1.2.3. Phenotypic correlations and relative contribution of A and E. The plot illustrates rP 
(phenotypic correlations) and the proportion of rP explained by A (additive genetic influences) and E (non-shared 
environmental influences) for the following trait dimensions: IA=inattention; HI=hyperactivity/impulsivity; 
RRB=repetitive and restricted behaviours; SIC=social interaction and communication. Note: 95% confidence 
intervals in parentheses. 
Aetiological correlations are presented in Table 6.1.2.3. Among the cross-trait genetic 
correlations (rg), the largest one was between HI and RRB (rg=0.56; 95% CI=0.46-0.65) and 
the smallest one was between HI and SIC (rg=0.33; 95% CI=0.23-0.43).  
 IA HI RRB SIC 
 r (95% CI) r (95% CI) r (95% CI) r (95% CI) 
IA  0.57 (0.53-0.61) 0.25 (0.19-0.30) 0.28 (0.23-0.33) 
HI 0.66 (0.60-0.71)  0.26 (0.21-0.31) 0.19 (0.14-0.24) 
RRB 0.49 (0.39-0.58) 0.56 (0.46-0.65)  0.29 (0.24-0.35) 
SIC 0.42 (0.33-0.51) 0.33 (0.23-0.43) 0.59 (0.49-0.70)  
Table 6.1.2.3. Additive genetic and non-shared environmental correlations. The table reports correlations 
between additive genetic influences (below the diagonal) and non-shared environmental influences (above the 
diagonal) influencing the following trait dimensions: IA=inattention; HI=hyperactivity/impulsivity; 
RRB=repetitive and restricted behaviours; SIC=social interaction and communication. Other abbreviations: 
r=correlation coefficient; 95% CI=95% confidence intervals. 
6.2 ADHD AND OTHER NDS: OUTCOMES AND TREATMENT 
EFFECTIVENESS 
Study 3 and 4 were designed to investigate whether the high comorbidity between ADHD and 
other NDs may have implications in terms of treatment effectiveness and if ADHD is 
specifically related to adverse health outcomes or if NDs as a group are associated with such 
outcomes.  
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6.2.1 ADHD medication and injuries and the role of co-occurring 
neurodevelopmental disorders (Study 3) 
6.2.1.1 Rationale 
Meta-analytic evidence has demonstrated that treatment with ADHD medication is associated 
with a 12% reduction in the risk of injuries.134 However, no previous study has tested if use of 
ADHD medication may prevent adverse health outcomes in children with other NDs, which 
often co-occur with ADHD in children.3-8 Considering the burden of injuries in this age 
group,135 Study 3 aimed at estimating the association between ADHD medication use and the 
risk of unintentional injuries in children and adolescents with ADHD, including those with co-
occurring NDs.  
Figure 6.2.1.1. Short-term association between ADHD medication use and injuries. The forest plot illustrates 
a summary of recent observational studies using data from population-based health-care databases on the short-
term association between ADHD medication use and injuries. Abbreviations: ES=effect size; 95% CI=95% 
confidence intervals. 
6.2.1.2 Methods 
To be included in the study, individuals had to reside in Sweden and have a diagnosis of ADHD 
and a diagnosis of unintentional injury. All individuals were followed from January 1st 2006 or 
their 5th birthday or the date of the first unintentional injury, whichever came last, to December 
31st 2013 or their 18th birthday or death, whichever came first.  
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Figure 6.2.1.2. Timeline Study 3. The figure illustrates the timeline for main data sources and for the sample 
included in Study 3. Abbreviations: NPR=national patient register; ICD=International Classification of Diseases; 
PDR=prescribed drug register. 
For each individual included in the study, follow-up time was divided into consecutive periods 
and the rate of injuries during periods on-treatment was compared to the rate of injuries during 
periods off-treatment (baseline). The comparison was within each individual. Stratified Cox 
regression was used to estimate the HR and 95% CIs for time to unintentional injury. The 
underlying time scale was time since last event (i.e., the last unintentional injury). Therefore, 
follow-up time was reset to zero whenever there was an event. The analyses were adjusted for 
age and seasonal pattern as time-varying covariates. As a secondary outcome, additional 
analyses were performed focusing on traumatic brain injuries (TBIs). Furthermore, separate 
analyses were performed in children and adolescents, in males and females, and in individuals 
with co-occurring NDs and ASD. Stata 15.1 (StataCorp., College Station, TX, USA) was used 
for all the analyses. 
6.2.1.3 Results 
There were 9,421 individuals included in the main analyses. Among them, more than 30% had 
been diagnosed with another ND (N=2,986) and the most common was ASD (N=1,390). 
Approximately 80% of the sample had at least one period on-medication and one period off-
medication. 
Main results on the association between ADHD medication use and injuries are presented in 
Table 6.2.1.3. ADHD medication use was associated with a lower rate of all unintentional 
injuries (HR=0.85; 95% CI=0.78-0.92), and of TBIs specifically (HR=0.27; 95% CI=0.20-
0.38). A negative association between ADHD medication use and injuries was observed among 
children (HR=0.66; 95% CI=0.58-0.74) and adolescents (HR=0.85; 95% CI=0.74-0.97), 
among males (HR=0.88; 95% CI=0.80-0.96) and females (HR=0.77; 95% CI=0.67-0.90), 
 32 
among individuals with any co-occurring ND (HR=0.88; 95% CI=0.77-1.01), and among the 
subgroup with co-occurring ASD (HR=0.77; 95% CI=0.62-0.96).  
  N of events Person-years at risk HR 95%CI 
Overall 16,344 53,069 0.85 (0.78-0.92) 
TBIs 1,696 9,075 0.27 (0.20-0.38)  
Age     
Children 7,525 23,086 0.66 (0.58-0.74) 
Adolescents 6,572 13,715 0.85 (0.74-0.97) 
Sex     
Males 11,472 37,951 0.88 (0.80-0.96) 
Females 4,872 15,118 0.77 (0.67-0.90) 
Co-occurring disorders 
Co-occurring NDs 5,212 17,313 0.88 (0.77-1.01) 
Co-occurring ASD 2,344 8,125 0.77 (0.62-0.96) 
Table 6.1.2.3. Association between ADHD medication use and injuries. The table reports number (N) of events, 
person-years at risk, hazard ratios (HRs), 95% confidence intervals (95%CIs) expressing the association between 
use of medication for ADHD and rate of unintentional injuries. Separate associations are reported for different age 
groups, sexes, individuals with co-occurring NDs, and for TBIs.  
6.2.2 Neurodevelopmental disorders and victimization (Study 4) 
6.2.2.1 Rationale 
NDs are associated with several adverse outcomes, including bullying and victimization. 
However, it remains unclear if all NDs or only some of them are associated with these 
outcomes. Therefore, Study 4 aimed at investigating the association between different NDs and 
the risk of violent victimization in adolescents and young adults, considering sex differences 
and the role of shared familial factors and mediating factors.   
6.2.2.2 Methods 
Information from NPR was used to identify diagnoses of ADHD, ASD, ID and other NDs after 
age two. All the exposures were time-varying. Individuals who were diagnosed with NDs 
before their 15th birthday were considered exposed for the entire follow-up. Individuals who 
were diagnosed with NDs after their 15th birthday were considered unexposed from their 15th 
birthday until the first diagnosis, and exposed afterwards. We defined violent victimization as 
any inpatient or outpatient visit (as recorded in the NPR) or death (as recorded in the CDR) due 
to any type of assault. The outcome date was defined as the date of first registered diagnosis 
(or the date of death).  
All individuals born in Sweden between 1985 and 1997 were followed from their 15th birthday 
until the first violent victimization event, death, migration outside Sweden, or December 31st 
2013, whichever came first. 
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Figure 6.2.2.2. Timeline Study 4. The figure illustrates the timeline for the main data sources and the sample 
included in Study 4. Abbreviations: NPR=national patient register; ICD=International Classification of Diseases; 
PDR=prescribed drug register. 
First, the crude association between the NDs and violent victimization was explored by 
estimating the cumulative incidence of being violently victimized in exposed and unexposed 
groups, separately for males and females. Then, Cox regression was used to estimate the HR 
and 95% CIs for time to violent victimization. The underlying time scale was time since the 
start of the follow-up, that is, the 15th birthday.  Then, adjusted estimates were obtained. Year 
of birth was included in the model as covariate and stratified Cox regression, entering each 
cluster of full siblings as a separate stratum, was used to control for unmeasured familial 
factors. Last, the following externalizing problems were added as covariates to the previous 
model (that is, the model adjusted for year of birth and unmeasured familial factors) in order 
to explore their possible mediating role: diagnosis of substance use disorder (SUD), diagnosis 
of conduct disorder (CD), and crime conviction.  These covariates were time-varying and date 
of the first diagnosis or first crime was used as the starting date of the exposed time.  
All the analyses were performed separately for males and females, for NDs combined, as well 
as for ADHD, ASD and ID separately and then for ADHD, ASD and ID included in the same 
model, that is, adjusted for other NDs. Stata 15.1 (StataCorp., College Station, TX, USA) was 
used to perform all the analyses. 
6.2.2.3 Results 
Among 1,344,944 individuals included in the study, 74,487 were diagnosed with a ND. ADHD 
was the most common diagnosis (N=45,991). There were 37,765 individuals who experienced 
violent victimization during the follow-up.  
At the end of the follow-up, 10.2% (95%CI=9.7-10.8) of males experienced violent 
victimization after being diagnosed with an ND, as compared to 6.0% (95%CI=5.9-6.1) of 
males who were not diagnosed with any ND. Among females, 9.2% (95%CI=8.6-9.9) 
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experienced violent victimization after being diagnosed with an ND, as compared to 2.4% 
(95%CI=2.4-2.5) among those who were not diagnosed with ND. ADHD was associated with 
the largest difference in the cumulative difference of violent victimization between those 
diagnosed and those who were not diagnosed, both in males and in females.  
 
Figure 6.2.2.3. Cumulative incidence of violent victimization. Figure 6.2.2.3 depicts the cumulative incidence 
of violent victimization among individuals diagnosed and not diagnosed with NDs. The top part of the figure 
reports the estimates in in males and the lower part of the figure reports the estimates for females. Note: Dashed 
line=exposed to NDs; solid line=unexposed to NDs. Abbreviations: NDs=neurodevelopmental disorders; 
ASD=autism spectrum disorder; ID=intellectual disability. 
Estimates from the crude model, showed that being diagnosed with any ND was associated 
with an increased risk of later violent victimization in males (HR=1.68; 95%CI=1.61-1.76) and 
females (HR=3.81; 95%CI=3.57-4.07). However, when analyzing specific disorders while 
adjusting for the other NDs, only ADHD was associated with an increased risk of later violent 
victimization in both sexes. ASD and ID were positively associated with violent victimization 
only in females, although adjusting for other NDs, attenuated these estimates.  
In the model adjusted for unmeasured familial factors, being diagnosed with any ND was 
associated with an increased risk of later violent victimization in males (HR=1.12; 
95%CI=0.98-1.27) and females (HR=1.68; 95%CI=1.34-2.10). When considering specific 
disorders, only ADHD was associated with an increased risk of violent victimization  in males 
(HR=1.46; 95%CI=1.25-1.70) and females (HR=2.11; 95%CI=1.57-2.83). Furthermore, there 
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was a positive association with ID among females, but the CI included one (HR=1.25; 
95%CI=0.78-2.01). All the associations were attenuated when compared to the unadjusted 
model, which suggests that familial factors shared by siblings may explain at least part of the 
association. 
Thereafter, when externalizing problems were added to the previous model (that is, adjusted 
for familial confounding) as covariates, all the associations attenuated, confirming that 
externalizing problems may mediate at least part of the association between NDs and violent 
victimization. When considering specific disorders, only ADHD was associated with an 
increased risk of violent victimization among males (HR=1.23; 95%CI=1.05-1.45) and females 
(HR=1.61; 95%CI=1.17-2.21). Furthermore, there was a positive association with ID in 
females, however the CI included one (HR=1.24; 95%CI=0.78-1.98). 
 Crude association Adjusted for other 
NDs 
Adjusted for 
familial factors 
Adjusted for 
familial factors and 
mediators 
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Males     
Any ND  1.68(1.61-1.76) - 1.12(0.98-1.27) 0.99(0.86-1.12) 
ADHD  2.45(2.33-2.58) 2.69(2.55- 2.84) 1.46(1.25-1.70) 1.23(1.05-1.45) 
ASD  0.84(0.75-0.95) 0.61(0.54-0.69) 0.81(0.60-1.10) 0.82(0.61-1.10) 
ID  0.81(0.70-0.93) 0.66(0.57-0.76) 0.52(0.37-0.72) 0.55(0.40-0.76) 
Females     
Any ND  3.81(3.57-4.07) - 1.68(1.34-2.10) 1.40(1.10-1.78) 
ADHD  5.12(4.73-5.55) 4.67(4.27-5.10) 2.11(1.57-2.83) 1.61(1.17-2.21) 
ASD  2.80(2.42-3.24) 1.24(1.05-1.47) 0.89(0.55-1.43) 0.83(0.52-1.33) 
ID  2.72(2.37-3.13) 1.75(1.50-2.04) 1.25(0.78-2.01) 1.24(0.78-1.98) 
Table 6.2.2.3. NDs and risk of violent victimization. Table 6.2.2.3 reports the estimates from the different models 
testing the association between NDs and risk of victimization. Abbreviation: HR=hazard ratio; CI=confidence 
interval; ND=neurodevelopmental disorder; ADHD=attention-deficit/hyperactivity disorder; ASD=autism 
spectrum disorder; ID=intellectual disability. 
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7 DISCUSSION 
7.1 MAIN FINDINGS AND IMPLICATIONS 
Overall, results from the four studies presented in this thesis demonstrate that comorbidity 
between ADHD and ASD may be attributable to common aetiological factors, which are, at 
least in part, of genetic origin. Comorbidity seems to be a key aspect of NDs as a diagnostic 
group, and it does not seem to affect treatment effectiveness with regard to ADHD medication 
and injuries. In addition to commonalities between ADHD and other NDs, there are some 
specific features regarding certain negative outcomes, as in the case of violent victimization, 
which seems to be more specifically associated with ADHD.   
7.1.1 Shared aetiology between ADHD and ASD 
When the work included in this thesis was initiated, there was a large body of evidence from 
twin studies supporting the existence of a genetic overlap between ADHD and ASD traits,90-
94,177-181,183 however little was known on the overlap between ADHD and ASD as clinically 
diagnosed disorders, with the exceptions of few family studies.95,96 Furthermore, only a few 
twin studies had investigated the association between ADHD and ASD traits in adults,91,92,179 
and only one181 had explored how specific trait dimensions related to one disorder may be 
associated with specific trait dimensions related to the other disorder. Results from molecular 
genetic studies, based on the comparison between clinically diagnosed patients vs controls, had 
provided support for shared rare chromosomal deletions and duplications between ADHD and 
ASD,99,100 but the only available study on the overlap in common genetic variants had failed to 
detect a genetic association.98 Therefore, it was unclear if the link between ADHD and ASD 
was limited to traits associated to the disorders as measured in the general population or it was 
also present between clinically diagnosed disorders.  
Results from Study 1 confirmed evidence from previous family studies, which had included 
only first degree relatives,95,96 that ADHD is more common among individuals with ASD and 
their relatives (up till half cousins). In addition, the association estimated in pairs of relatives 
who were more genetically similar (for example, twins and full siblings) was stronger than the 
association estimated in pairs of relatives who were less genetically similar (for example, half 
siblings and cousins). Furthermore, the associations were larger for high-functioning than for 
low-functioning ASD. New evidence has been accumulating in the last year on the overlap 
between ADHD and ASD, both from family studies176 and from molecular genetics studies,97 
in agreement with the findings presented in this thesis. The most recent GWAS of ASD, 
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published earlier in 2019, has, for the first time, reported a positive genetic correlation between 
ASD and ADHD, estimated to be equal to 0.36.97 
Results from Study 2 converge with the only previous existing study on dimension-specific 
overlap between ADHD and ASD traits. Study 2 showed that, although there were phenotypic 
and genetic correlations across all traits examined, the size of the correlations varied. For 
example, the association between RRB and SIC (that is, between two traits within ASD) was 
similar to the association between RRB and HI (that is, between one trait related to ASD and 
one trait related to ADHD). The latter association was, in turn, higher than the association 
between SIC and HI.   
In summary, findings from Study 1 and 2 indicate that the comorbidity between ADHD and 
ASD may be due to familial factors shared by the disorders and by the traits related to these 
disorders. These factors are likely to be of genetic origin, although non-genetic factors may 
also play a role. This is in line with recent findings supporting the existence of a heritable 
general factor of psychopathology, which includes ADHD.184-186 Results from Study 1 on 
differences between low- and high-functioning ASD and results from Study 2 on different trait 
dimensions related to ASD and ADHD suggest that the overlap between these disorders may 
be explained by different links between specific manifestations or symptom dimensions related 
to each disorder. 
These studies add to the increasing evidence on cross-disorder overlap and within-disorder 
heterogeneity in psychiatry, which is having an impact on diagnostic systems, and, hopefully, 
will continue to inform psychiatric nosology. For example, from the 4th to the 5th edition of 
DSM there was a change in the diagnostic criteria of ADHD. In the 4th version, ASD was an 
exclusion criterion for the diagnosis of ADHD, while DSM-5 has removed this exclusion 
criterion and allows a diagnosis of ADHD in individuals with ASD. However, this change has 
not been implemented in ICD-11, which has been recently released.21 Our results, in 
combination with previous research, indicate that ICD-11 should probably adopt the DSM-5 
approach on this. 
Future research aimed at characterizing causes of ADHD, other NDs and their co-occurrence 
might benefit from combining different genetically informative designs and from the 
availability of rich phenotypic data, ideally including measures of continuous variation of traits 
in the population as well as clinically significant symptoms. In order to understand the genetic 
architecture of neuropsychiatric disorders, some studies have focused on parsing disorder-
specific from cross-disorder187 or general effects.186 In addition, within-disorder phenotypic 
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and genetic heterogeneity has not only been given increased attention in genetic studies of 
psychiatric phenotypes,97,188 but also in genetic studies of other complex traits.189  
7.1.2 ADHD and other NDS: outcomes and treatment effectiveness 
Most of the previous research on outcomes of ADHD and treatment effectiveness has neglected 
the role of comorbidity with other NDs, either by excluding individuals with co-occurring 
disorders or by lumping together individuals with and without co-occurring disorders.  
Findings from Study 3 suggest that children and adolescents diagnosed with ADHD and co-
occurring NDs may benefit from use of ADHD medication to the same extent in terms of 
prevention of unintentional injuries. While no previous observational study had examined the 
association between ADHD medication use and injuries in individuals with co-occurring NDs, 
these results are in line with evidence from RCTs, which suggests that ADHD medications are 
superior to placebo in reducing core symptoms of ADHD among children with co-occurring 
NDs.190-192 
Results from Study 4 indicate that, although NDs as a group seem to be associated with an 
increased risk of being violently victimized, particularly among females, ADHD may be 
driving the association. In addition, results from the analyses adjusted for familial factors and 
for mediation via externalizing problems suggest that there may be a direct link between 
ADHD and victimization. These findings are in line with previous research on the association 
between NDs and other types of victimization.114,115,193,194  
Altogether, Study 3 and 4 support the view of NDs as a diagnostic group characterised by 
homogeneity in terms of response to medications and adverse health outcomes. Results from 
Study 3 suggest that comorbidity with other NDs does not affect ADHD medication 
effectiveness in reducing the risk of injuries and results from Study 4 indicate that violent 
victimization seems to be associated with NDs as a group. Therefore, the risk of victimization 
should be assessed in this group of patients. On the other hand, Study 4 demonstrates that 
ADHD may be more specifically associated with an increased susceptibility to violent 
victimization. More research is needed to understand which aspects of ADHD may be stronger 
risk factors for this adverse outcome. 
Future epidemiologic studies may expand current knowledge on outcomes of ADHD and 
treatment effectiveness by taking into consideration the presence of other symptoms or 
disorders or other aspects of the disorder such as severity and presentation. Furthermore, the 
role of familial factors, of genetic or non-genetic origin, and of possible mediating factors 
should be assessed in order to explore the mechanisms that may explain observed associations. 
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7.2 METHODOLOGICAL CONSIDERATIONS 
7.2.1 Measures 
7.2.1.1 Register measures 
In Study 1, 3, and 4 the main exposure and outcome measures were derived from different 
Swedish nation-wide registers, in particular from the NPR, the PDR and the CDR. For 
diagnoses of NDs, we expect that the most severe cases are more likely to be captured from 
this data source. This may imply that, for example, individuals who have a recorded diagnosis 
of NDs in the NPR may be more likely to present with higher impairment and with co-occurring 
conditions. This may have caused an overestimation of comorbidity rates in Study 1. For Study 
3 and 4 this may limit the representativeness of the observed associations between ADHD 
medication and reduced risk of injuries (Study 3) and between NDs and violent victimization 
(Study 4) to the most severe groups of patients only. 
In study 3, information on frequency of medication dispensations was used to define ADHD 
treatment status. The choice of the maximum interval between medications was based on 
previous studies. In addition, sensitivity analyses using varying lengths of the interval (for 
example 3, 4 and 6 months) have supported the robustness of the results. However, non-
adherence may lead to misclassification of the exposure. In other words, if the dispensation 
would cover a period of time longer than estimated, due to poor adherence, time that should 
have been classified as medicated would in fact be classified as non-medicated. One scenario 
in which this may be problematic is if the majority of events were to occur at the beginning of 
a new non-medicated period, which followed a previous medicated period. If this was the case, 
an alternative explanation for the protective effect of ADHD medication on the risk of injuries 
observed in Study 3 may be misclassification of time that was exposed to ADHD medication 
as unexposed time.  
The definition of the outcome in Study 3 and 4 was based on ICD codes used to specify the 
causes of morbidity and mortality. In Study 3 the outcome of interest was on injuries with 
unintentional cause only, while in Study 4 the outcome of interest was assault. Currently, there 
is no evaluation of the quality of this specific information and validation studies are needed to 
assess reliability of these register measures. However, it can be assumed that when the cause 
of an event cannot be reliably ascertained, it will be recorded as “event of undetermined intent”. 
Therefore, although some events that are in fact unintentional injuries or assault may be 
recorded as “event of undetermined intent”, it is less likely that the cause of an event will be 
recorded as unintentional or assault if there is uncertainty about the real cause of the event.  
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7.2.1.2 Self-rated measures 
ADHD and ASD trait dimensions used in Study 2 were self-rated using a web-based 
questionnaire (a paper version could be provided upon request). There are at least two key 
limitations to consider related to the data source for Study 2. First, the reliance on self-rating 
only. Cross-twin correlations based on self-rating (that is, when each twin rates themselves 
separately) tend to be lower than those based on parent’s rating (that is, when the same parent 
rates both twins). As a consequence, cross-twin correlations based on self-rating may be 
underestimated. This, in turn, may lead to an inflation of the E component, which captures any 
source of dissimilarity between the members of the twin pairs, including rater bias, that is, a 
personal tendency (in this case not influenced by genetics) to provide similar answers to 
different items in a questionnaire. A second important issue is the low response rate. 
Supplementary analyses showed that non-participants were less likely to have higher education 
attainment and to be employed, and they were more likely to be diagnosed with a psychiatric 
disorder. These observations clearly limit the generalizability of our results to individuals with 
higher socio-economic status and less severe levels of ADHD and ASD symptoms. 
Despite the aforementioned limitations, the convergence between results from Study 1, based 
on clinical diagnoses from the registers, which are likely to capture more severe cases, and 
results from Study 2, based on self-rated trait dimensions measured in the general population, 
supports the robustness of our conclusions on the phenotypic and genetic overlap between 
ADHD and ASD.    
7.2.2 Methods 
Various designs and analytical approaches have been applied in this thesis, each of which has 
inherent assumptions, advantages and limitations.  
Study 1 and 2 are based on the notion that different clusters of relatives are characterised by 
different genetic sharing. For example, MZ twin pairs are genetically identical, while DZ twins 
and full siblings share, on average, half of their genetic background. In addition to this notion, 
Study 2 assumes that MZ and DZ twins share common aspects of rearing environment (that is, 
the C component) to the same extent (often referred to as Equal environment assumption). In 
other words, the only source contributing to higher resemblance on a trait within members of 
MZ twin pairs vs DZ twin pairs is genetics. This assumption has been demonstrated to be valid 
for several psychological traits and psychiatric disorders.195,196 Another assumption of twin 
design is the absence of assortative mating for the traits under examination. Assortative mating 
has been reported for several psychiatric disorders, both within each disorder and between 
  41 
different disorders, including ASD and ADHD.197 Violation of this assumption in twin design 
may lead to underestimation of heritability, since higher similarity between parents will cause 
an increase in the average genetic resemblance between DZ twins. However, it is unclear if this 
may have caused an underestimation of the genetic contribution to the phenotypic correlations 
between ADHD and ASD trait dimensions in Study 2. Last, twin design assumes that the effects 
of gene-gene or gene-environment interaction, if any, are negligible. When these types of 
mechanisms are considered to be important, other genetic methods, may be adopted. For 
example, if gene-environment correlation or interaction is suspected, extensions of the classic 
twin method may be used. Depending on the nature of the environment (that is, shared or not 
by the members of the twin pairs) that correlate or interact with the genetic component, 
different types of data may be needed to test gene-environment interplay. And the nature of the 
relevant environment will also determine which parameters may be affected by such interplay. 
While the lack of a test of these aspects in Study 2 may be considered a limitation, this was not 
among the intended aims of the study. On the other hand, gene-gene and gene-environment 
interplay do represent interesting directions for future research, which may benefit from a 
combination of different methods of genetic epidemiology.  
Study 3 and 4 have used within-cluster comparison to adjust for cluster-invariant confounders. 
When using this approach, only clusters with variation in the covariates included in the model 
are informative for the analysis. Therefore, two main limitations of this approach are 
generalizability of the results to the informative clusters only and the precision of the estimates. 
Of note, in Study 3 most of the study participants did have variation in their medication status 
throughout the follow-up. In Study 4 it remains unclear if sibling clusters with variation in the 
diagnostic status of NDs are representative of the source population. Another limitation related 
to within-cluster comparison is that, although cluster-invariant confounders are adjusted for by 
design, other confounders that vary within the cluster may be relevant for the research questions 
investigated in Study 3 and 4. In Study 3, for example, lack of data on psychosocial treatment 
during the follow-up is a limitation, as this may be both related to medication use and injury 
risk. In Study 4, factors non-shared by siblings that may increase vulnerability to ADHD and 
to being violently victimized may explain at least part of the association. For example, 
characteristics of the parents and/or of the offspring related to birth, such as parental age at 
childbearing or birth weight, may be additional factors to consider. Furthermore, it has been 
demonstrated that confounding by factors that are not perfectly shared by members of the 
clusters and random error related to exposure measurement may introduce bias.198 Last, 
analytical methods applied in within-cluster comparison assume absence of carryover effect 
within the cluster. For example, in the case of the sibling-comparison design, used in Study 4, 
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the assumption implies that the exposure and outcome status of one sibling in the cluster does 
not affect the exposure and outcome status of the other siblings in the cluster. In many 
instances, this may lead to bias.199 One scenario that may be problematic is when exposure 
status in one sibling may influence the outcome in the other siblings, or when there is an 
association between the outcome on one sibling and the outcome in the other sibling. Some of 
these associations may be more plausible than others, and some may be ruled out. For example, 
in Study 4, estimates may be biased by carryover effect if the diagnosis of a ND in one sibling 
would influence the subsequent vulnerability to violent victimization of the other sibling or if 
there was an effect of violent victimization in one sibling on subsequent vulnerability to violent 
victimization in the other sibling. These two potential associations were not formally tested in 
Study 4, and this may be considered a limitation of the study. On the other hand, they do not 
seem to be plausible alternative explanations for the associations observed.  
7.3 ETHICAL CONSIDERATIONS  
7.3.1 Data collection and handling 
The work presented in this thesis includes studies based on data from a record linkage of several 
Swedish registers and from a survey within the STR. The record linkage has obtained approval 
by the Regional Ethical Review Board in Stockholm in 2013. In the case of national registers 
informed consent is not needed according to Swedish law. In contrast, individuals participating 
in the survey from the STR, YATSS, were asked informed consent to use the data for research 
purposes. Informed consent was asked after having provided relevant information about the 
study, in order to ensure that individuals were aware of possible risks and, therefore, to enable 
them to make an informed and independent decision about participation. Moreover, individuals 
may decide to be excluded from the STR and may decline invitation to participate to surveys 
within the STR. Ethical approval was obtained from the Regional Ethical Review Board in 
Stockholm for the YATSS study. 
According to the Personal Data Act in Sweden (Swedish abbreviation: PUL) and to the 
European General Data Protection Regulation (GDPR), the information included in the record 
linkage of national registers is considered personal data. The definition of personal data 
includes any information that can be directly or indirectly attributed to a person. For the projects 
included in this thesis, data were anonymized and located in a protected server. Data handling 
was done following recommendations for good practice in data management and archiving 
formulated by the department.  
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7.3.2 Results communication and interpretation 
In this thesis, results from four different studies are described. Therefore, there are aspects 
related to the communication and interpretation of the studies’ results, both within the scientific 
community and with the wider audience, which should be considered. For example, in Study 1 
we used the term “high-” vs “low-functioning” ASD to refer to ASD without or with ID, 
respectively. While this terminology has been extensively used in the literature on ASD, it has 
also been criticized based on the observation that intelligence alone may not be as important as 
other skills in predicting the level of functioning of individuals with ASD in daily 
activities.200,201 On the other hand, the term “low-functioning” disregards individual strengths 
and may be perceived as stigmatizing. More reflection and debate on these aspects are needed 
in order to agree on language and terminology. Terminology should be appropriate for 
scientific purposes, where some level of simplification may be needed. However, it is vital to 
select terms that do not convey stigma and that promote inclusion and diversity.  
Another potential issue concerns the interpretation of results from Study 4 on the increased 
vulnerability of individuals with NDs to violent victimization. Investigating whether NDs as a 
group or some specific disorders may increase the risk of being violently victimized should not 
be considered an attempt to shift the accountability for these acts from the perpetrators to the 
victims.115 The goal of the study was to bring the attention of mental health professionals (and 
other health and social professionals too, ideally) on groups of individuals who may have 
experienced victimization, in order to provide specific support and prevent secondary effects. 
In addition, understanding mechanisms through which ADHD symptoms may increase the risk 
of victimization may help clinicians to monitor potential indicators of higher vulnerability to 
adverse events among ADHD patients. 
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8 CONCLUSIONS  
The work presented in this thesis supports the view of NDs as a diagnostic group characterised 
by both general and specific aspects. Partially overlapping aetiological factors, of genetic and 
non-genetic origin, may explain the comorbidity between ADHD and ASD. Among children 
and adolescents with ADHD and co-occurring NDs, treatment with ADHD medication seems 
to be as effective in reducing the risk of adverse health outcomes as it is in the larger ADHD 
group. There is an association between NDs as a group and violent victimization in adolescence 
and young adulthood, but there is also a specific association with ADHD, which seems to be 
in part explained by shared familial factors and mediators and in part attributable to a direct 
link.  
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